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Introductory paragraph
Nephrotic syndrome is the consequence of damage to the glomerular filtration barrier, and it refers 
to the clinical symptoms of heavy proteinuria, hypoalbuminemia, edema and hyperlipidemia. The 
steroidresistant form of nephrotic syndrome (SRNS) has a poor prognosis, as it often leads to end-
stage renal disease (ESRD)1,2. Mutations in more than 20 genes have been identified in monogenic 
forms of SRNS, most of which encode podocyte proteins3–5. NPHS2, encoding podocin, is the most 
frequently mutated of these genes and is responsible for 12–18% of SRNS cases3,6,7. Podocin 
accumulates in dimeric or oligomeric forms in lipid raft microdomains at the podocyte slit diaphragm, 
which is the key component of the glomerular filtration barrier. On the basis of its predicted 
structure, podocin belongs to the stomatin protein family, with a hairpin-like intramembrane loop 
and intracellular N and C termini. The C-terminal portions of both stomatin and podocin are 
responsible for dimerization6,8–12.
Individuals with NPHS2 mutations typically develop SRNS before 6 years of age and progress to ESRD 
during their first decade of life6. The phenotype can be less severe in the setting of a trans 
association of an NPHS2 mutation and the polymorphism c.686G>A (p.Arg229Gln, rs61747728), a 
genotype we hereafter denote as p.[Arg229Gln];[mut] that causes SRNS with a median age at 
diagnosis of 13 years (range, 0–39 years) and progression to ESRD by 26 years (range, 10–50 
years)7,13–18. Nevertheless, the p.Arg229Gln variant in the homozygous state does not cause SRNS19,20.
On the basis of the 15× higher allele frequency of p.Arg229Gln (357/13,006, 2.7%) than the 
cumulative allele frequency of the known disease-causing variants13–18,21–43 (24/13,006, 0.18%) in the 
National Heart, Lung, and Blood Institute (NHLBI) exome variant server (see URLs), one would expect 
the prevalence of late onset SRNS secondary to p.[Arg229Gln];[mut] to exceed that of early onset 
SRNS secondary to two NPHS2 mutations (referred to here as [mut];[mut]) by 30× (i.e., 2rq as 
compared to q2, where r and q correspond to the allele frequency of p.Arg229Gln and that of the 
mutations, respectively). However, late onset SRNS secondary to p.[Arg229Gln];[mut] (n = 71)
2was reported to be 3.5× less frequent than early onset SRNS secondary to [mut];[mut] (n = 247) in 
the French and other large SRNS cohorts13–18,21–43. This substantial (100×) difference between the 
expected and observed ratios suggested to us that p.[Arg229Gln];[mut] is not disease causing in the 
majority of cases.
To test this hypothesis, we screened for p.Arg229Gln in the unaffected parents of affected children 
with NPHS2 mutations, i.e., unaffected individuals who are obligate mutation carriers. Indeed, out of 
129 parents, we found a total of 6 (4.7%), aged 42–62 years, to be compound heterozygous for 
alleles encoding p.Arg229Gln and one of the following alterations in trans: p.Arg138Gln, p.Arg138* (n 
= 2), p.Arg168His, c.534+1G>T or p.Arg238Ser. These findings clearly demonstrate the incomplete 
penetrance of SRNS in p.[Arg229Gln];[mut] individuals. Nevertheless, the high allele frequency of 
p.Arg229Gln in late onset SRNS (5.7–7.5%)16–18 points to its pathogenicity in some cases. Recognizing 
that this discrepancy could reflect the influence of the trans-associated mutations, we compared the 
exonic localization of the mutations between cases with [mut];[mut] and cases with 
p.[Arg229Gln];[mut] in 318 families from French and other SRNS cohorts13–18,21–43 and found a striking 
difference (P = 1.2 × 10−35; Table 1). Notably, whereas mutations in the last two exons (7 and 8) 
were rare in cases with [mut];[mut], these mutations were associated with p.Arg229Gln in the vast 
majority of cases with p.[Arg229Gln];[mut]. This difference points to a pivotal role of the trans-
associated mutation in determining the pathogenicity of p.Arg229Gln.
To determine which mutations specifically were pathogenic in association with p.Arg229Gln, we 
compared their allele frequencies between cases with p.[Arg229Gln];[mut] and cases with 
[mut];[mut]13–18,21–43 (Table 2 and Supplementary Table 1). Missense mutations affecting Ala284, 
Ala288, Arg291, Ala297, Glu310, Leu327 or Gln328 (‘associated mutations’) were enriched in cases 
carrying p.[Arg229Gln];[mut], confirming the pathogenicity of their associations. In contrast, the 
allele encoding p.Val290Met, despite being the most common missense mutation of exons 7 and 8, 
was never reported in association with p.Arg229Gln, making the pathogenicity 
ofp.[Val290Met];[Arg229Gln] unlikely (Table 2). We indeed found two second-degree relatives of a 
case homozygous for p.Val290Met41 who carried [p.Val290Met];[Arg229Gln] with no proteinuria 
(<20 mg l−1) at the ages of 37 and 43 years, confirming its non-pathogenic nature (Supplementary 
Fig. 1).
Out of the 56 mutations located in exons 1–6, only 4 were associated with p.Arg229Gln in cases with 
SRNS, and these accounted for only 8 of 71 (11%) total p.Arg229Gln-associated alleles (Tables 1 and 
2)13–18,21–43. Even these four associations are unlikely to be pathogenic for several reasons. First, 
we found two of the associations (p.[Arg138Gln]; [Arg229Gln] and p.[Arg238Ser];[Arg229Gln]) in 
3unaffected parents. Second, the phenotypesof the six cases with available clinical information 
(previously published13,18 and identified in the French cohort here) suggest a non–NPHS2-related 
pathology, either because of interstitial calcification, tubular atrophy and hypogammaglobulinemia in 
one case with p.[Arg238Ser];[ Arg229Gln] or because of a clinical course that is highly reminiscent of 
an immune-mediated process, including recurrence after transplant in three cases with 
p.[Arg138Gln];[Arg229Gln] or early response to steroid therapy in two cases with 
p.[Gln215*];[Arg229Gln] or p.[Lys126Ilefs*7];[Arg229Gln]). Third, if p.[Arg138Gln];[Arg229Gln] were 
pathogenic, the number of cases with this association would be expected to exceed the number of 
cases with p.[Arg138Gln];[mut], but we found the inverse to be true (Table 2). Thus, the rare 
association of a mutation in exons 1–6 and p.Arg229Gln in 8 of 3,004 (0.3%) families with SRNS13–18,21–
43 is very likely to be an incidental finding without a causal role. Notably, the cumulative allele 
frequency of the associated mutations among all mutated alleles in cases with [mut];[mut] (9/494 
alleles, 1.8%; Table 2) is in agreement with the 100× difference between the expected and observed 
prevalence of cases with p.[Arg229Gln];[mut]. Nevertheless, it cannot be excluded that other rare 
mutations of exons 7 and 8 are also pathogenic when associated with p.Arg229Gln (Table 2). As all 
the associated mutations were C-terminal substitutions, we hypothesized that they exert a 
deleterious effect on p.Arg229Gln podocin. We therefore studied the membrane targeting of 
p.Arg229Gln podocin in human podocyte cell lines transiently coexpressing different podocin 
constructs. In perfect accordance with the clinical data, p.Arg229Gln podocin was localized properly 
to the plasma membrane when coexpressed with wild-type podocin, p.Arg238Ser podocin or 
p.Val290Met podocin but was retained in the cytoplasm when coexpressed with p.Ala284Val, 
p.Ala288Thr, p.Arg291Trp, p.Ala297Val or p.Glu310Lys podocin (Supplementary Fig. 2). These latter 
podocin mutants showed a reticular and dispersed vesicular localization pattern similar to that of 
p.Arg291Trp podocin that is known to be trapped in the endoplasmic reticulum (ER) and 
vesicles11,44 and did not markedly modify the localization of coexpressed wild-type podocin 
(Supplementary Fig. 2). Furthermore, p.Arg138Gln podocin, which is known to be retained in the 
ER10,11,44,45, did not alter the localization of p.Arg229Gln podocin, which is in accordance with the non-
pathogenic nature of their association (Supplementary Fig. 2). We found similar results in podocytes 
stably coexpressing wild-type podocin or p.Arg229Gln podocin with podocin mutants (Fig. 1). 
Notably, we also confirmed the non-membrane targeting of endogenous podocin in podocytes 
isolated from urine of a case with p.[Arg229Gln];[Ala284Val], a result that is contrary to its 
membranous localization in control patients with p.[Arg229Gln];[=]
4(Fig. 2 and Supplementary Fig. 3). Thus, all the clinical observations, in vitro studies and ex vivo 
studies strongly support a deleterious effect of certain podocin mutants on p.Arg229Gln podocin, 
mimicking a dominant-negative effect.
To understand this interaction at an atomic resolution, we examined the calculated structure of their 
dimers. On the basis of structural modeling, the homodimer of the C-terminal fragment (residues 
161–383) of wild-type podocin consists of two head domains (residues161–270) connected by their 
intertwined helical tails (residues
271–332), forming a coiled-coil–type association (Fig. 3a). Arg229 is stabilized in the core of the 
globular head domain by at least two hydrogen bonds involving Glu233, Glu237 or Asp244 (Fig. 3b).
In p.Arg229Gln podocin, Glu233 and Glu237 are released from these contacts, flip toward the helical 
tail domain and form electrostatic interactions with Arg286 and Lys289, rigidifying the structure by 
forming an additional head-tail interaction (Fig. 3b,c). Nevertheless, both the p.Arg229Gln podocin 
homodimer and the heterodimer of p.Val290Met podocin with p.Arg229Gln podocin formed a 
topologically similar molecular arrangement to that of the wild-type homodimer (Fig. 4a). Moreover, 
the structure of the heterodimer of p.Ala284Val podocin with wild-type podocin was highly 
reminiscent of that of the wild-type podocin homodimer as well (Fig. 4a). In contrast, heterodimers 
of p.Ala284Val podocin with p.Arg229Gln podocin and of p.Ala297Val podocin with p.Arg229Gln 
podocin, as well as the p.Ala284Val podocin homodimer, showed characteristically different 
structures (Fig. 4b), which is in keeping with their pathogenicities. The derived structures support the 
conclusion that the combination of the p.Arg229Gln variant with the associated mutations leads to 
an altered mode of dimerization, which we propose contributes to the retention of p.Arg229Gln 
podocin within cytoplasmic compartments.
The role of the associated mutations in the pathogenicity of p.Arg229Gln can explain several clinical 
observations: (i) the difference between the observed and expected prevalence of cases with 
p.[Arg229Gln];[mut]; (ii) the steroid sensitivity of nephrotic syndrome in a case with 
p.[Arg229Gln];[truncating mutation]24; (iii) the lack of pseudo-dominant inheritance in families with 
NPHS2 mutations in exons 1–6 despite the non-negligible allele frequency of p.Arg229Gln13–18,21–43; 
and (iv) the late onset nature of SRNS in cases with p.[Arg229Gln];[mut]16–18, as p.Arg229Gln podocin 
homodimers are still expected to function properly.
In conclusion, the NPHS2 allele encoding p.Arg229Gln is only pathogenic when associated with 
specific mutations. Thus, we describe an autosomal-recessive disorder in which the pathogenicity of 
one allele depends on that of the other. This phenomenon has direct clinical implications. Unlike 
current counseling practices, a couple carrying an NPHS2 mutation located in exons 1–6 in one 
5member and p.Arg229Gln in the other are not at risk of having an affected child. Conversely, genetic 
counseling of couples with p.Arg229Gln and associated mutations will be challenging, as the 
potential transmission rate of 50% for two unaffected parents, or the potential transmission rates of 
25%, 75% or 100% for an affected and an unaffected parent, are not expected in autosomal-recessive 
disorders (Supplementary Fig. 4). Other autosomal-recessive disorders may also be inherited in such 
a mutation-dependent recessive fashion, especially if the encoded protein forms oligomers. In this 
study, we provide an example of how common variants can be implicated in rare monogenic 
diseases, thus opening a new aspect in the assessment of the pathogenicity of sequence variants.
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Table 1. Distribution of NPHS2 mutations in patients with [Arg229Gln];[mut] and in patients with 
[mut];[mut] (n: number of mutated alleles)
[Arg229Gln];[mut] 
Total of 71 patients 
[mut];[mut]
Total of 247 patients 
n ratio n ratio p
exons 1-6 8 11.3% 421 85.2% 3.8 x 10-36
6exons 7-8 63 88.7% 73 14.8%
Table 2. Allele frequency of NPHS2 mutations in patients with [p.Arg229Gln];[mut] and in patients with 
([mut];[mut])
patients with 
[Arg229Gln];[mut] patients with [mut];[mut]






Lys126Ilefs*7 1 1.4% 0 0.12
Arg138Gln a 5 7.0% 171 34.6% 3.9 x 10-7
Gln215* 1 1.4% 6 1.2% 1
Arg238Ser a 1 1.4% 3 0.6% 0.42
all the other mutations in 
exons 1-6 (n=53 type) b




p.Val268Asp*16 0 2 0.4% 1
p.Leu270Phe 1 1.4% 0 0.0% 0.12
p.Pro271Leu 0 1 0.2% 1
p.His276Leu 0 2 0.4% 1
p.His276Alafs*8 0 2 0.4% 1
p.Glu281Ala 0 2 0.4% 1
p.Ala284Val 26 36.6% 8 c 1.6% 3.3 x 10-19
p.Arg286Thrfs*17 3 4.2% 20 4.0% 1
p.Ala288Thr 4 5.6% 0 0.0002
p.Lys289* 0 2 0.4% 1
p.Val290Met 0 13 2.6% 0.39
p.Arg291Trp 4 5.6% 1 0.2% 0.001
c.873+2T>A 0 1 0.2% 1




c.874-1G>C 0 2 0.4% 1
p.Ala295Thr 1 1.4% 0 0.12
p.Ala297Val 4 5.6% 0 0.0002
p.Ala300Pro 1 1.4% 0 0.12
p.A301del 0 4 0.8% 1
p.Leu305Pro 1 1.4% 0 0.12
p.Glu310Ala 1 1.4% 0 0.12
p.Glu310Lys 5 7.0% 0 2.8 x 10-5
p.Glu310Val 2 2.8% 0 0.016
p.Glu310 total 4.3 x 10-8
p.Ala317Leufs*31 1 1.4% 7 1.4% 1
p.Leu321Phefs*27 1 1.4% 0 0.12
p.Arg322Gly 1 1.4% 2 0.4% 0.33
p.Leu324GludelinsHis 0 1 0.2% 1
p.Leu327Phe 3 4.2% 0 0.002
p.Gln328Arg 2 2.8% 0 0.016
p.Phe344Leufs*4 1 1.4% 0 0.12
p.Leu346Tyrfs*2 1 1.4% 0 0.12
7p.Pro372Ilefs*16 0 1 0.2% 1
Total: 71 100% 494 100%
a: these two mutations were also found in unaffected parents in trans-association with Arg229Gln, b: detailed in 
Supplementary data, c: eight alleles of four homozygous patients. Mutations significantly enriched in patients 
with [p.Arg229Gln];[mut] are in gray, mutations enriched in patients with ([mut];[mut]) are in yellow
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Figure 1.
Figure 1. Membrane targeting of wild-type podocin and p.Arg229Gln podocin as a function of the associated mutation in podocytes stably 
coexpressing podocin mutants. (a–f) Hemagglutinin (HA)-tagged wild-type (WT) (a–c) and p.Arg229Gln (d–f) podocin are shown in red, and the 
coexpressed GFP-tagged podocin proteins are shown in green. The plasma membrane is labeled with wheat germ agglutinin (WGA) and shown in 
blue. Both wild-type and p.Arg229Gln podocin are localized to the plasma membrane when coexpressed with wild-type podocin (a,d, white pixels 
correspond to the merge of red, green and blue) and with p.Arg138Gln podocin, despite the retention of the latter protein in the ER (b,e, magenta 
pixels correspond to the merge of red and blue). Although membrane targeting of wild-type podocin is only moderately decreased in cells 
coexpressing p.Ala297Val podocin (c, magenta pixels), that of p.Arg229Gln podocin is abolished (f). Scale bar, 20 μm. (g,h) Membrane targeting of 
podocin proteins quantified as the percentage of the plasma membrane (WGA) that is positive for GFP-tagged (g) or HA-tagged (h) podocin proteins 
within 30 cells per group. GFP-tagged and HA-tagged podocin proteins are indicated in green and red, respectively. The coexpressed podocin 
proteins are in parentheses, followed by the panel label corresponding to each quantification. *P < 3.3 × 10−11 as compared to WT (WT-GFP); †P = 1.8 
× 10−6 as compared to WT (WT-HA); #P = 3.5 × 10−11 as compared to p.Arg229Gln (WT).
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Figure 2. Membrane targeting of endogenous podocin in urinary podocytes of cases with SRNS carrying p.Arg229Gln. (a) Endogenous podocin is 
shown in red, and the WGA-labeled plasma membrane is shown in blue. Podocin is well targeted to the plasma membrane in the three control 
patients with non–NPHS2-associated glomerulopathy (C1–C3), two of whom are heterozygous carriers of p.Arg229Gln, in contrast to the patient 
with p.[Arg229Gln];[Ala284Val] (Pt). Scale bar, 20 μm. (b) Membrane targeting of podocin proteins shown as the percentage of the plasma 
membrane (WGA) that is positive for endogenous podocin. The n values below each patient indicate the number of cells quantified. #45 cells 
quantified in three different immunostaining experiments on two different cultures of urinary podocytes; *P ≤ 6.7 × 10−13 as compared to each of 
the three control patients.
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Figure 3. Structure of the wild-type podocin homodimer and the effect of p.Arg229Gln. (a) Calculated structure of the wild-type podocin 
homodimer (monomers A and B are in light and dark green, respectively) shown as ribbon diagram (left) and an all-atom representation (excluding 
non-polar H atoms for clarity; right). Altered residues that point inward to the head domain (229) and the coiled-coil region (284, 288, 291, 297 and 
328) are colored magenta on both monomers. Alterations at these latter positions are expected to impair the mode of dimerization, in contrast to 
Val290 (yellow), which points outward from the coiled-coiled domain. Glu310 and Leu327 (lilac) seem like fenders to the coiled-coil region: Glu310 
participates in a charge network of Glu296, Lys299, Glu303, Arg306 and Glu310, creating a − + − + − charge motif at the surface of the molecule, 
whereas at the opposite side, Leu327 is part of a hydrophobic patch. (b,c) The H-bond network stabilizing Arg229 within the head domain of wild-
type podocin (green) is rearranged in the p.Arg229Gln mutant (cyan) (b) and restricts the pliability of the overall conformation of p.Arg229Gln 
podocin (cyan) compared to that of the wild-type podocin monomer (in green) (c). c is an ensemble of characteristic conformations sampled in the 
last 10 ns of the simulation.
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Figure 4. Superimposed average structures of the non-pathogenic and pathogenic dimers. Frontal and lateral structural views of podocin dimers 
are shown overlaid based on their globular region of monomer A for comparison. (a) Non-pathogenic dimers of p.Arg229Gln with p.Arg229Gln 
podocin (cyan), p.Val290Met with p.Arg229Gln podocin (orange) and p.Ala284Val with wild-type podocin (purple) are similar in structure to the 
wild-type podocin homodimer (green). (b) The structures in a are in contrast to the structures formed by the pathogenic dimers of p.Ala284Val with 
p.Arg229Gln podocin (red) and p.Ala297Val with p.Arg229Gln podocin (yellow) and the p.Ala284Val and p.Ala284Val podocin homodimer (blue) 
shown superimposed on the wild-type podocin homodimer (green). Accordingly, the root mean square deviations of the backbone atoms compared 
to those in wild-type podocin were 2.7 Å, 2.9 Å and 3.3 Å for the non-pathogenic dimers shown in a, respectively, and 4.9 Å, 6.9 Å and 9.5 Å for the 
pathogenic dimers shown in b, respectively. Mobility of the backbone atoms (reflecting the well-defined nature of the structure) remained similar: 
the mobility was slightly decreased (~30%) in both the dimers of p.Arg229Gln with p.Arg229Gln podocin and p.Val290Met with p.Arg229Gln podocin 
and was increased (~20%) in the dimer of p.Ala284Val with wild-type podocin with respect to wild-type podocin. A slight increase in mobility is seen 
for the pathogenic dimer of p.Ala284Val with p.Ala284Val podocin (~24%) as well, which is accompanied by the largest root mean square deviation 
from the wild-type dimer. This indicates a stabilized but quite altered three-dimensional structural arrangement. With respect to the wild-type 
dimer, the remaining pathogenic dimers, p.Ala284Val with p.Arg229Gln podocin and p.Ala297Val with p.Arg229Gln podocin, show intermediate root 
mean square deviations but a striking increase (~140%) in mobility, resulting in conformational states that are markedly different from that of wild-
type podocin.
